Recurrent hyperglycemia despite apparently appropriate insulin administration is an uncommon but clinically important problem that may reflect subcutaneous insulin resistance rather than inadequate prescribing, nonadherence, or simple progression of diabetes. This phenomenon is characterized by markedly impaired insulin absorption or action after subcutaneous injection, often resulting in persistent severe hyperglycemia, high insulin requirements, glucose variability, and recurrent ketosis. The condition has been described in association with obesity, lipohypertrophy, repeated injections into abnormal tissue, autoimmune disease, systemic inflammation, and rare disorders of insulin absorption. Recognition requires a structured assessment of injection technique, insulin storage, adherence, glucose measurement, infusion devices, and alternative causes of treatment failure. Clinical evaluation should distinguish true subcutaneous resistance from pseudoresistance, in which insulin appears ineffective because of administration errors or inconsistent use. Management may include correction of injection technique, rotation of injection sites, treatment of lipohypertrophy, supervised insulin administration, use of concentrated insulin formulations, temporary intravenous insulin, continuous subcutaneous insulin infusion, and careful monitoring for hypoglycemia. A mechanism-based approach is essential because excessive dose escalation without identifying the underlying cause can increase risk when insulin absorption suddenly improves. This review summarizes the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategy, treatment principles, emerging approaches, and guideline-based implications of this challenging presentation.
Insulin therapy is effective only when the prescribed dose reaches the circulation in a predictable and biologically active form. When plasma glucose remains high despite apparently adequate or escalating doses, clinicians commonly consider missed injections, incorrect dosing, defective insulin, dietary excess, infection, glucocorticoid exposure, or progressive beta-cell failure. These explanations are frequent, but they do not account for every case. A small subset of patients develop profound impairment in insulin delivery from the subcutaneous depot, producing a clinical picture of recurrent hyperglycemia despite documented administration.
Subcutaneous insulin resistance is best understood as a disorder of insulin absorption and local tissue handling rather than a single standardized disease entity. It may occur when repeated injections damage subcutaneous tissue, when local fibrosis or amyloid deposition alters diffusion, or when inflammatory and immune processes interfere with insulin uptake. The diagnosis is particularly important in patients with severe hyperglycemia who require unusually large doses, experience unpredictable responses, or demonstrate a dramatic fall in insulin requirements after a change in injection site or route of administration. Because the condition is rare and overlaps with more common forms of treatment failure, careful clinical reasoning is required.
The true prevalence of subcutaneous insulin resistance is unknown. Published evidence consists mainly of case reports, small case series, and observational descriptions, indicating that it is uncommon compared with conventional insulin resistance caused by obesity, metabolic syndrome, infection, or glucocorticoid therapy. Nevertheless, its clinical burden can be substantial. Patients may experience prolonged exposure to marked hyperglycemia, recurrent diabetic ketoacidosis or hyperosmolar hyperglycemic state, emergency admissions, dehydration, electrolyte disturbances, and loss of confidence in insulin treatment.
High insulin requirements are not diagnostic by themselves. Severe obesity, hepatic steatosis, chronic inflammation, endocrinopathies, anti-insulin antibodies, and medications can all increase insulin needs. However, a sudden requirement for several hundred units daily, especially when accompanied by poor response at selected injection sites and a rapid response to intravenous insulin, should prompt consideration of impaired subcutaneous absorption. The burden also extends to healthcare systems because patients often undergo repeated admissions, extensive investigations, and frequent regimen changes before the local injection problem is recognized.
After subcutaneous injection, insulin must diffuse through extracellular tissue, enter local capillaries and lymphatic channels, and reach the systemic circulation. The rate and consistency of this process depend on tissue composition, blood flow, injection depth, insulin formulation, local inflammation, and the condition of the injection site. Repeated injections into the same area can produce lipohypertrophy, lipoatrophy, fibrosis, edema, or localized amyloid deposits. These structural changes may create an irregular depot from which insulin is absorbed slowly, incompletely, or unpredictably.
Lipohypertrophy is particularly relevant because it may be painless and visually subtle. Insulin injected into lipohypertrophic tissue can have delayed absorption and reduced bioavailability compared with injection into normal subcutaneous tissue. Local amyloidosis, caused by deposition of insulin-derived amyloid after repeated injections, may produce firm nodules and can markedly impair absorption. Some patients alternate between ineffective absorption from abnormal areas and unexpectedly rapid absorption after moving to healthy tissue, creating substantial glycemic variability.
Systemic mechanisms may also contribute. Anti-insulin antibodies can bind insulin and alter its distribution, although this is distinct from a purely local subcutaneous defect. Severe inflammation, altered microvascular perfusion, edema, and immune-mediated disease may change insulin pharmacokinetics. In contrast, conventional systemic insulin resistance involves impaired insulin signaling in muscle, liver, and adipose tissue and generally affects insulin action regardless of whether insulin is administered subcutaneously or intravenously. This distinction explains why some patients respond promptly to intravenous insulin while remaining resistant to large subcutaneous doses.
Important risk factors include prolonged insulin therapy, repeated injections into a limited number of sites, failure to rotate sites, use of short needles or improper injection angles, and lack of routine inspection and palpation of injection areas. Lipohypertrophy is more likely when patients reuse needles, inject through clothing, or continue using a site because it is less painful. Insulin pump users may develop infusion-site inflammation, cannula failure, or localized tissue changes that mimic pharmacologic resistance.
Additional risk factors include obesity, high total daily insulin doses, autoimmune thyroid disease, type 1 diabetes, recurrent diabetic ketoacidosis, poor injection technique, cognitive impairment, limited health literacy, and barriers to obtaining supplies. Clinicians should also evaluate concurrent infection, corticosteroid treatment, acromegaly, Cushing syndrome, thyrotoxicosis, pheochromocytoma, and atypical antipsychotic exposure. These conditions may coexist with local absorption problems and amplify the apparent insulin requirement.
The typical presentation is persistent or recurrent hyperglycemia despite a documented insulin dose that would ordinarily be expected to produce a substantial effect. Patients may report that some injections work while others do not, or that glucose values improve rapidly after hospitalization and supervised therapy. Glycemic patterns can be highly variable, with severe hyperglycemia followed by delayed hypoglycemia when previously deposited insulin is absorbed or when the patient changes to healthy tissue.
Physical examination may reveal palpable rubbery, thickened, indurated, or nodular areas at common injection sites. However, the absence of visible abnormalities does not exclude the diagnosis. A careful history should address the exact site, depth, timing, device, needle use, insulin storage, dose preparation, and relationship between injection location and glucose response. Symptoms of osmotic diuresis, dehydration, weight loss, fatigue, nausea, abdominal pain, and altered mental status indicate possible metabolic decompensation and require urgent assessment.
Diagnosis begins by excluding pseudoresistance. Clinicians should directly observe insulin preparation and administration, verify the insulin product and concentration, inspect storage conditions and expiration dates, review injection or pump technique, and compare the prescribed regimen with actual use. Continuous glucose monitoring or structured capillary testing can help correlate insulin administration, injection site, meals, and subsequent glucose change.
Laboratory evaluation should include plasma glucose, glycated hemoglobin, serum or blood ketones, electrolytes, renal function, venous or arterial pH when indicated, and assessment for infection or other precipitants. C-peptide interpretation depends on endogenous insulin production and glucose concentration. When clinically appropriate, testing for anti-insulin antibodies may help identify immune-mediated abnormalities, although results do not always establish causality. Examination for lipohypertrophy and amyloid-associated nodules is essential; ultrasound or biopsy may be considered when the diagnosis remains uncertain or a firm mass is present.
A supervised comparison of subcutaneous and intravenous insulin response can be informative in specialist settings. A marked glucose fall with intravenous insulin but not with observed subcutaneous administration supports impaired absorption or local resistance. This assessment must be performed in a monitored environment because delayed absorption from prior injections can result in late hypoglycemia.
Management should begin with correction of reversible local factors. Patients should stop injecting into lipohypertrophic, indurated, scarred, or nodular areas and use healthy sites according to evidence-based rotation principles. Education should emphasize inspection and palpation of sites, single-use needles, appropriate needle length, complete dose delivery, and avoidance of repeated injections into the same region. Clinicians should not simply increase the dose before confirming that insulin is being delivered correctly.
Acute ketosis, severe dehydration, altered mental status, or marked hyperosmolarity requires hospital treatment according to established diabetic ketoacidosis or hyperosmolar hyperglycemic state protocols. Intravenous insulin may bypass the impaired subcutaneous depot and provide predictable action. Once metabolic stability is achieved, a carefully monitored transition to subcutaneous treatment is necessary. If very high doses are required, concentrated formulations such as U-200 or U-300 insulin, and in selected circumstances U-500 regular insulin, may reduce injection volume and improve practicality. Concentrated insulin requires clear prescribing, device-specific education, and safeguards against dosing errors.
Continuous subcutaneous insulin infusion can be useful when basal-bolus injections provide inconsistent absorption, although infusion sites remain vulnerable to local tissue changes and catheter failure. Infusion-site rotation and frequent glucose or sensor monitoring are essential. Treatment of systemic contributors, including infection, endocrine disease, inflammatory disorders, and medication-related hyperglycemia, should occur concurrently. When local amyloidosis or another structural lesion is suspected, specialist referral and individualized management are appropriate.
Advances in continuous glucose monitoring, connected insulin pens, smart insulin pumps, and automated insulin delivery systems are improving recognition of discordance between insulin administration and glucose response. These technologies can identify repeated post-injection glucose excursions, missed boluses, infusion-set failure, and delayed absorption patterns. They do not replace physical examination or supervised assessment, but they provide longitudinal data that can clarify cause and effect.
Research is also examining more predictable delivery routes and formulations, including faster-acting insulin analogues, concentrated basal insulins, and alternative delivery systems designed to reduce variability in absorption. In exceptional cases, intravenous insulin or specialized implanted delivery approaches may be considered in tertiary centers, although these strategies are not routine treatment. Better characterization of insulin-derived amyloidosis, tissue remodeling, and antibody-mediated pharmacokinetic changes may eventually support targeted diagnostic biomarkers and individualized therapy.
Current diabetes standards consistently recommend routine inspection of injection and infusion sites, systematic rotation of sites, avoidance of areas affected by lipohypertrophy or lipoatrophy, and education on correct insulin administration. They also support continuous glucose monitoring for many patients using intensive insulin therapy, particularly when recurrent hyperglycemia or hypoglycemia complicates management. Severe hyperglycemia with ketosis or hyperosmolar features should be treated promptly using established hospital protocols rather than outpatient dose escalation.
Guideline-based care further emphasizes individualized glycemic targets, assessment of adherence without judgment, review of medication access and affordability, and evaluation for secondary causes of insulin resistance. In suspected subcutaneous resistance, expert endocrinology consultation is advisable. Dose changes should be conservative after a new injection site, formulation, or route is introduced because insulin absorption may improve abruptly and expose the patient to delayed hypoglycemia. Documentation of education, site findings, glucose patterns, and follow-up plans is an important safety measure.
Recurrent hyperglycemia despite apparently appropriate insulin administration should not automatically be attributed to nonadherence or progressive systemic insulin resistance. Subcutaneous insulin resistance is an uncommon but clinically consequential explanation, particularly when insulin requirements are extreme, injection-site abnormalities are present, glucose responses are unpredictable, or intravenous insulin is substantially more effective. Diagnosis requires exclusion of pseudoresistance, detailed examination of injection technique and tissue, assessment for metabolic and endocrine contributors, and, when necessary, supervised comparison of administration routes. Treatment depends on correcting local tissue and technique problems, managing acute metabolic emergencies, selecting suitable insulin formulations or delivery systems, and monitoring closely for delayed hypoglycemia. Greater awareness among clinicians can shorten diagnostic delays, prevent unsafe dose escalation, and improve glycemic outcomes through practical, mechanism-based care.
1.
CDC Alerts on Dramatic Rise in Human Parvovirus B19
2.
Three out of ten breast cancers detected between screenings, study finds
3.
What is a "cancer vaccine" and is it the same as a COVID vaccine?
4.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
5.
Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?
1.
Erythropoiesis Modulation in Chronic Anemia Management
2.
The Life-Saving Powers of Anemia: How to Combat the Disease.
3.
Molecular Glue Therapy in Leukemia
4.
Precision Oncology: Cancer Screening, Genetic Counseling & Hereditary Cancer Syndromes Integration
5.
Unlocking the Potential of SABCS 2022: Innovative Strategies for Cancer Research
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation